Brief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
22/09/2026 12:07
BRIEF-Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society Sept 22 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:
ELEDON PRESENTS UPDATED LONG-TERM PHASE 2 BESTOW EXTENSION STUDY RESULTS AT THE INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY
Source text: ID:nGNX5TZNtk
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial